deltatrials
Terminated PHASE3 INTERVENTIONAL 3-arm NCT02097121

OnabotulinumtoxinA for the Treatment of Urinary Incontinence Due to Overactive Bladder in Pediatric Patients (12 to 17)

BOTOX® in the Treatment of Urinary Incontinence Due to Overactive Bladder in Patients 12 to 17 Years of Age

Sponsor: Allergan

Conditions Overactive Urinary Bladder Urinary Incontinence
Interventions BOTOX®
Updated 21 times since 2017 Last updated: Nov 23, 2022 Started: May 23, 2014 Primary completion: Feb 10, 2022 Completion: Feb 10, 2022
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

This trial was terminated. No reason was provided.

Other terminated trials from Allergan

See all terminations from Allergan

A PHASE3 clinical study on Overactive and Urinary Bladder, this trial is terminated or withdrawn. The trial is conducted by Allergan and has accumulated 21 data snapshots since 2014. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshot~Feb 2017 – ~Sep 2017 · 7 months · monthly snapshot~Sep 2017 – ~Jun 2018 · 9 months · monthly snapshot~Jun 2018 – ~Jul 2018 · 30 days · monthly snapshot~Jul 2018 – ~Apr 2019 · 9 months · monthly snapshot~Apr 2019 – ~Nov 2019 · 7 months · monthly snapshot~Nov 2019 – ~Jan 2020 · 2 months · monthly snapshot~Jan 2020 – ~Mar 2020 · 2 months · monthly snapshot~Mar 2020 – ~Apr 2020 · 31 days · monthly snapshot~Apr 2020 – ~Jun 2020 · 2 months · monthly snapshot~Jun 2020 – ~Nov 2020 · 5 months · monthly snapshot~Nov 2020 – ~Jan 2021 · 2 months · monthly snapshot~Jan 2021 – ~Feb 2021 · 31 days · monthly snapshot~Feb 2021 – ~Sep 2021 · 7 months · monthly snapshot~Sep 2021 – ~Jan 2022 · 4 months · monthly snapshot~Jan 2022 – ~Jun 2022 · 5 months · monthly snapshot~Jun 2022 – ~Feb 2023 · 8 months · monthly snapshot~Feb 2023 – ~Jul 2024 · 17 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshot~Sep 2025 – present · 10 months · monthly snapshot

Change History

21 versions recorded

  1. Sep 2025 — Present [monthly]

    Terminated PHASE3

  2. Sep 2024 — Sep 2025 [monthly]

    Terminated PHASE3

  3. Jul 2024 — Sep 2024 [monthly]

    Terminated PHASE3

  4. Feb 2023 — Jul 2024 [monthly]

    Terminated PHASE3

  5. Jun 2022 — Feb 2023 [monthly]

    Terminated PHASE3

    Status: Active Not Recruiting → Terminated

▶ Show 16 earlier versions

  1. Jan 2022 — Jun 2022 [monthly]

    Active Not Recruiting PHASE3

    Status: Recruiting → Active Not Recruiting

  2. Sep 2021 — Jan 2022 [monthly]

    Recruiting PHASE3

  3. Feb 2021 — Sep 2021 [monthly]

    Recruiting PHASE3

  4. Jan 2021 — Feb 2021 [monthly]

    Recruiting PHASE3

  5. Nov 2020 — Jan 2021 [monthly]

    Recruiting PHASE3

  6. Jun 2020 — Nov 2020 [monthly]

    Recruiting PHASE3

  7. Apr 2020 — Jun 2020 [monthly]

    Recruiting PHASE3

  8. Mar 2020 — Apr 2020 [monthly]

    Recruiting PHASE3

  9. Jan 2020 — Mar 2020 [monthly]

    Recruiting PHASE3

  10. Nov 2019 — Jan 2020 [monthly]

    Recruiting PHASE3

  11. Apr 2019 — Nov 2019 [monthly]

    Recruiting PHASE3

  12. Jul 2018 — Apr 2019 [monthly]

    Recruiting PHASE3

  13. Jun 2018 — Jul 2018 [monthly]

    Recruiting PHASE3

  14. Sep 2017 — Jun 2018 [monthly]

    Recruiting PHASE3

  15. Feb 2017 — Sep 2017 [monthly]

    Recruiting PHASE3

  16. Jan 2017 — Feb 2017 [monthly]

    Recruiting PHASE3

    First recorded

May 2014

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Allergan
Data source: Allergan

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Aberdeen, United Kingdom , Anchorage, United States , Aurora, United States , Bielefeld, Germany , Bordeaux, France , Calgary, Canada , Clayton, Australia , Edegem, Belgium , Emmendingen, Germany , Fort Worth, United States and 29 more locations